Cargando…

Current therapeutics against HCV

Hepatitis C is a positive stranded enveloped RNA virus belonging to the Flaviviridae family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Chayan, Singh, Maitri, Das, Debisukti, Chaudhuri, Sujit, Mukhopadhyay, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279913/
https://www.ncbi.nlm.nih.gov/pubmed/34307769
http://dx.doi.org/10.1007/s13337-021-00697-0
Descripción
Sumario:Hepatitis C is a positive stranded enveloped RNA virus belonging to the Flaviviridae family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are reported to be effective against all HCV genotypes. Here, we review the HCV life cycle and its immunogenic potential and various mechanisms via which the virus interferes in the signalling process. A comprehensive overview of current anti-HCV therapeutics, such as, Direct Acting Antiviral (DAA) as well as Host Targeting Agents (HTA), along with their scope, known mechanism of action and limitations are presented. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13337-021-00697-0.